EDIT News and Press, Editas Medicine Inc. From 01/04/23

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 41st Annual J.P. Morgan Healthcare Conference o...

Summary CRISPR Therapeutics AG is a gene editing company based on CRISPR/Cas9 technology. CRISPR method seems to be the preferred in Gene Editing. CRSP has a rich pipeline. CRISPR seems to be the preferable Gene Editing Method and CRISPR Therapeutics AG ( CRSP ) could ...

Summary Beam Therapeutics announced the recruitment of its first BEACON trial patient in the middle of November 2022. BEAM's announcement was followed by Editas Medicine's declaration of positive safety and efficacy data from its first two patients enrolled and treated under the Ruby tr...

Summary Editas is a CRISPR/Cas9 gene editing pioneer that's on the right side of a complex patent dispute currently. Its lead candidate EDIT-101 read out disappointing results from a study in eye disease and development has been halted. That has rocked Editas and its share price - a...

The following slide deck was published by Editas Medicine, Inc. in conjunction with this event. For further details see: EDIT-301 Clinical Update

Editas Medicine, Inc. (EDIT) EDIT-301 Clinical Update Call December 6, 2022 8:00 A.M. ET Company Participants Ron Moldaver - Investor Relations Gilmore O’Neill - President and Chief Executive Officer Baisong Mei - Senior Vice President and Chief Medical Officer ...

Some biotech stocks are positioned to deliver outsized returns in a short period, but those that do generally come with a healthy amount of risk. Consider, for instance, Editas Medicine (NASDAQ: EDIT) and BioXcel Therapeutics (NASDAQ: BTAI) . These two small-cap biotechs are l...

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant Both patients treated with EDIT-301 successfully engrafted and are free of vaso-occlusive events during the follow-up ...

Shares of Editas Medicine (NASDAQ: EDIT) , a clinical-stage biotech company, fell by 15.5% in November, according to data from S&P Global Intelligence . The stock closed October at $12.55 a share, then opened November at $13. It fell steadily throughout the month, dropping to a lo...

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday, December 6, at 8:00 a.m. ET to present initial clinical data from the Phase 1/2 RUBY trial of ...